Xenon Stock Craters 30.7% as Depression Trial Pause Overshadows NDA Filing
XENE is trading near its 52-week low of $35.97 (11% above the low) on elevated volume (13× avg).
Summary
Xenon Pharmaceuticals shares plunged 30.7% to $39.75, their worst day since 2017, after the company paused new patient enrollment in ongoing studies for major depressive disorder and bipolar depression. The pause overshadowed the company's NDA submission for azetukalner in focal seizures, which had been a key milestone. The market is treating the depression program setback as a major blow to the drug's broader commercial potential. This follows the earlier report this morning that first disclosed the enrollment pause, but the stock's severe reaction confirms the market's negative reassessment. The company's cash position of $1.2 billion provides runway, but the setback raises questions about the lead asset's expansion opportunities.
At the time of this announcement, XENE was trading at $39.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $35.97 to $72.66. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.